The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder Clinical Trial

Official title:

Relationship Among Changes in Brain Network Activation, Changes in Core Depressive and Cognitive Symptoms and Safety and Tolerability in Adults With Major Depressive Disorder Treated With Open-label, Flexible-dose Vortioxetine

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02559947
• Other study ID #: IISR-2014-100702
• Status: Not yet recruiting
• Phase: Phase 4
• First received: September 23, 2015
• Last updated: September 23, 2015
• Start date: October 2015
• Est. completion date: October 2018

Study information

• Verified date: September 2015
• Source: Psychiatric Medicine Associates, L.L.C.
• Contact: Michael E Topel, PsyD
• Phone: 847-679-8000
• Email: michael_topel[@]rush.edu
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to explore patterns of BNA changes from baseline to endpoint on 1) efficacy of core MDD symptoms and, 2) improvement of cognitive dysfunction with acute treatment of flexible dose vortioxetine in adult outpatients with MDD and subjective complaints of cognitive dysfunction.

Description:

Vortioxetine is a novel antidepressant with hypothetical multimodal mechanism of action. It is thought to work through a combination of multiple pharmacological modes of action: 5-HT reuptake inhibition, 5-HT3 and 5-HT7 receptor antagonism, 5-HT1A receptor agonism, and 5-HT1B receptor partial agonism [43]. In vivo nonclinical studies have demonstrated that vortioxetine enhances levels of the neurotransmitters 5-HT, NE, DA, acetylcholine and histamine in specific areas of the brain [43]. These affinities are all considered to be of clinical relevance and involved in the mechanism of action at therapeutic doses.

Vortioxetine has been shown to improve core depressive symptoms and improve cognitive function in adult outpatients with MDD and subjective complaints of cognitive function. This pilot study is intended to evaluate the extent to which BNA technology can provide clinically valuable information and provide information toward designing a subsequent confirmatory study that will further elucidate the effect of vortioxetine on MDD and cognitive function in this population. This exploratory study will ascertain the acute changes in core depression symptoms, cognitive function, tolerability, and safety using flexible-dose vortioxetine in adult outpatients with MDD with subjective complaints of cognitive functioning, as measured by BNA changes and standard outcome measures for depression and cognition.

The study consists of 8 weeks of open-label treatment for MDD with response to treatment measured by standard research depression scales and BNA EEG readings taken at certain points during the trial. An important aim in this study is to explore what correlations may exist between changes in measured brainwave patterns and reported change in depressive symptoms.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: October 2018
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The subject has single episode or recurrent MDD (acute onset of recurrence of recurrent MDD with poor inter-episode recovery) (inter-episode periods cannot meet full MDD criteria) as the primary diagnosis according to DSM-IV-TR criteria. The current MDE will be confirmed using the Mini International Neuropsychiatric Interview (MINI V6.0.0).

• The subject has a MADRS total score =26.

• Subject reports subjective cognitive dysfunction (such as difficulty concentrating, slow thinking, and difficulty in learning new things or remembering things).

• The reported duration of the current MDE is at least 3 months and no longer than 24 months.

• The subject is a man or woman between 18 and 65 years old, inclusive.

• Right-handed, normal (corrected) vision, and normal hearing.

Exclusion Criteria:

• The subject has a score of =70 on the DSST at the Baseline Visit.

• Failure to respond to or inability to tolerate an adequate trial of vortioxetine in the past.

• Exposure to an investigational compound 30 days prior to enrollment

• Exposure to any psychoactive or otherwise excluded medication within five half-lives of the baseline visit or during the study. Excluded medications include: antidepressants, anxiolytics, anticonvulsants, barbiturates, chloral hydrate, lithium, antipsychotics, benzodiazepines, hypnotics, MAO-Inhibitors, muscle relaxers, Triptans, centrally-acting antihistamines, central alpha-2 agonists, decongestants, psychostimulants, dopamine agonists, opioid pain medications, oral corticosteroids, L-methylfolate, SAMe, 5-HTP, St. John's Wort,

• The subject has 1 or more of the following:

• Primary psychiatric disorder other than MDD as defined in the DSM-IV-TR (as assessed by the MINI, Version 6.0.0).

• Current or history of attention deficit hyperactivity disorder (ADHD), pervasive developmental disorder, manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.

• Current diagnosis of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-TV-TR that has not been in sustained full remission for at least 6 months (for abuse) and 12 months (for dependence) prior to Screening.

• Positive urine drug screen prior to Baseline.

• Presence or history of a clinically significant neurological disorder (including epilepsy).

• Neurodegenerative disorder (Alzheimer Disease, Parkinson Disease, multiple sclerosis, Huntington Disease, etc).

• Any unstable medical condition as determined by the principal investigator (PI).

• Any DSM-IV Axis II disorder that might compromise the study as determined by the PI.

• The subject has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.

• The subject has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.

• The subject has a significant risk of suicide according to the PI's clinical judgment.

• The subject, in the opinion of the PI, poses a risk of harm to others.

• The subject has initiated formal cognitive or behavioral therapy, systemic psychotherapy within less than 6 months of study screening, or has plans to initiate such therapy during the study.

• The subject has received electroconvulsive therapy, vagus nerve stimulation, or repetitive transcranial magnetic stimulation within 12 months prior to Screening.

• The current MDE is considered by the PI to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the recommended dose.

• The subject is pregnant or breastfeeding, or is intending to become pregnant before, during, or within 30 days after participating in this study.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Vortioxetine
Vortioxetine is a novel antidepressant with hypothetical multimodal mechanism of action. It is thought to work through a combination of multiple pharmacological modes of action: 5-HT reuptake inhibition, 5-HT3 and 5-HT7 receptor antagonism, 5-HT1A receptor agonism, and 5-HT1B receptor partial agonism [43]. In vivo nonclinical studies have demonstrated that vortioxetine enhances levels of the neurotransmitters 5-HT, NE, DA, acetylcholine and histamine in specific areas of the brain [43]. These affinities are all considered to be of clinical relevance and involved in the mechanism of action at therapeutic doses.

Locations

Country	Name	City	State
United States	Psychiatric Medicine Associates, LLC	Skokie	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
Psychiatric Medicine Associates, L.L.C.	ElMindA Ltd, Takeda Pharmaceuticals North America, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Montgomery and Asberg Depression Scale (MADRS)	The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness that was shown to be sensitive to treatment effects. Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60. An experienced clinician can use the MADRS after a training session. It takes approximately 15 to 20 minutes to administer and rate the MADRS.	7 days	No